Dielegance Biotechnology

Dielegance Biotechnology is a clinical-stage biopharmaceutical company based in Suzhou, China, specializing in the discovery and development of innovative protein degradation therapies. The company focuses on Proteolysis-Targeting Chimera (PROTAC) technology to address "undruggable" targets and overcome drug resistance in oncology. Its lead pipeline programs include degraders targeting the androgen receptor (AR) for prostate cancer and the estrogen receptor (ER) for breast cancer. By leveraging its proprietary platform, Dielegance aims to provide next-generation treatments for patients with advanced malignancies who have exhausted standard-of-care options.